But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. So should ORIC Pharmaceuticals ...

Shares of ORIC stock opened at $7.03 on Thursday. The firm has a market cap of $499.32 million, a price-to-earnings ratio of -3.86 and a beta of 1.25. ORIC Pharmaceuticals has a 52-week low of $6. ...

On Tuesday, H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock.

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635 (c) (4), and were granted as a material inducement to employment in ...

Shares of ORIC stock opened at $7.68 on Friday. ORIC Pharmaceuticals has a 1-year low of $6.33 and a 1-year high of $16.65. The firm’s 50-day simple moving average is $9.27 and its 200-day ...

and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of ...

ORIC Pharmaceuticals outlines clinical development plans for ORIC-944 and ORIC-114, targeting high unmet needs in mCRPC and NSCLC. ORIC Pharmaceuticals has refined its registrational development ...

ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...